Healthcare
Live Price
Offline$464.61
+0.63% today
1Y Change
+23.06%
Window
Jun 23, 2025 → May 29, 2026
Coverage: 236 bars · Jun 23, 2025 → May 29, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Thermo Fisher Scientific Inc. (TMO) is a Healthcare stock with a market cap of $174.37B and listed on NYSE. The stock last traded around $464.61 and up 23.1% across the available one-year price window (Jun 23, 2025 → May 29, 2026). Baseline metrics include revenue growth of +3.9%, EPS growth of +7.2%, a dividend yield of 0.4%. What stands out right now is revenue +3.9%, EPS +7.2%, free cash flow -13.4% with operating margin 17.8% and ROIC 7.3%. The dividend is present but secondary, with a yield around 0.4%. Valuation is more restrained than many high-expectation growth names at P/E 25.4 and price/sales 3.9. Stock Foundry combines TMO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TMO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TMO Max Drawdown
-31.45%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TMO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$39.2B
-12.7% YoY
FY Net Income
$7.7B
+11.2% YoY
Free Cash Flow
$7.0B
+1.6% YoY
Revenue Growth
+3.9%
EPS Growth
+7.2%
Gross Margin
39.4%
Net Margin
15.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 44.6B | 42.9B | 42.9B | 44.9B | 39.2B |
| Gross Profit | 16.8B | 17.7B | 17.2B | 19.0B | 19.6B |
| Operating Income | 8.1B | 7.7B | 7.4B | 8.5B | 10.3B |
| EBITDA | 11.5B | 11.8B | 11.2B | 11.9B | 12.0B |
| Net Income | 6.7B | 6.3B | 6.0B | 7.0B | 7.7B |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 9.9B | 4.0B | 8.1B | 8.5B | 4.5B |
| Total Assets | 110.3B | 97.3B | 98.7B | 97.2B | 95.1B |
| Total Liabilities | 56.8B | 47.6B | 51.9B | 53.0B | 54.1B |
| Shareholder Equity | 53.4B | 49.6B | 46.7B | 44.0B | 40.8B |
| Total Debt | 40.9B | 32.8B | 36.4B | 36.1B | 36.3B |
| Net Debt | 31.0B | 28.8B | 28.3B | 27.5B | 31.8B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9.5B
+4.2% YoY
Capital Expenditures
2.5B
-12.5% YoY
Free Cash Flow
7.0B
+1.6% YoY
Key ratios
Gross Margin
39.4%
Operating Margin
17.8%
Net Margin
15.2%
ROE
13.3%
Debt / Equity
0.83x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.